Mark Merritt, the CEO of Pharmaceutical Care Management Association, the trade association that represents pharmacy benefits managers like Express Scripts, which recently partnered with Imprimis to provide its compounded version of Daraprim at a cheaper cost, made it very clear that he would rather
see generic competition than compounded versions.
After controlling for other factors, a
generic drug in the highest marketing
competition group was expected to
see a decrease of 32 percent in price over the study period, while a
generic drug in the lowest market
competition was expected to
see a price increase of 47 percent over the same period.